News & Updates

A strong, positive link between BMI and the risk of colorectal cancer (CRC) incidence and related deaths has been found in Asian populations.

In the phase III ASC4FIRST study, asciminib – the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP) – trumped all investigator-selected tyrosine kinase inhibitors (IS-TKIs; imatinib, nilotinib, dasatinib, and bosutinib) for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP).

Patients with a diagnosis of lymphangioleiomyomatosis (LAM) are at higher risk of developing lung cancer, reveals a recent study.

Combination treatment with abemaciclib and a nonsteroidal aromatase inhibitor (NSAI) as initial therapy, compared with NSAI alone, helps extend survival in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer, results of the MONARCH 3 study have shown.

A novel artificial intelligence (AI) classifier can detect hepatocellular carcinoma (HCC) signatures in routine blood tests up to 1 year before clinical diagnosis, as shown in a study from Hong Kong.